Mabion’s Tech Transfer Team wins Biologics CDMO Excellence Europe 2025
Mabion is proud to announce that our team has been awarded Tech Transfer Team of the Year at the Biologics CDMO Excellence Europe 2025 Awards, held during the Biologics CDMO Europe 2025 conference in Munich. Organised by IMAPAC, the awards recognise the visionaries, innovators, and leaders shaping the future of outsourced biomanufacturing across Europe.
A purpose-driven campaign with measurable impact
This distinction is especially meaningful as winners are nominated and selected by industry peers – experts who understand the complexity, breakthroughs, and dedication required to advance biologics manufacturing. With more than 500 entries, 300 industry leaders, and representation from over 50 countries, the awards remain one of the most influential benchmarking platforms in the global biopharmaceutical sector.
Biologics CDMO Europe 2025 is known for its curated, closed-door setting, bringing together no more than 300 hand-picked specialists to exchange insights, build partnerships, and define the direction of biomanufacturing. In such a focused environment, Mabion’s recognition underscores the team’s exceptional capability in driving high-impact, high-quality technology transfers for global partners.
Mabion extends its gratitude to the industry community for this honour and congratulates all fellow award recipients whose contributions continue to elevate standards in biologics production.
Jakub Knurek is a marketing and business development expert specializing in CDMO operations with scientific and biopharmaceutical background. During the COVID-19 pandemic, he contributed to the development of the Novavax protein vaccine. As a side project, he runs his own pharma company.
As the author of numerous articles, he is recognized as an important voice of the younger generation of scientists. He is a member of Mabion’s representation at industry trade shows, including BIO International Convention 2025 in Boston, 2nd Global Biologics India 2025 in Hydrabad, CPHI 2024 in Milan, CPHI 2023 in Barcelona, Life Sciences Baltics 2023 in Vilnius. He actively participates in academic, business and industry discussions, such as the “Building the Future Pharma Workforce” panel at CPHI Milan 2024.
Sources and further reading
IMAPAC. Biologics CDMO Excellence Europe 2025: Honouring the People & Progress Redefining Industry Standards. 2025.
FAQ
A tech transfer to a CDMO is the process of moving a drug development and manufacturing process from one party to another, typically from a client (sponsor) to the CDMO. This involves sharing comprehensive technical information, like process knowledge, analytical methods, and manufacturing details, to ensure the CDMO can reliably and consistently produce the product to quality and regulatory standards.
The team was recognised for its rigorous technical expertise, cross-functional collaboration, and ability to deliver seamless, timely, and compliant transfers for global biopharmaceutical partners.
This award recognises outstanding achievements in successfully transferring biomanufacturing processes between sites or organisations, ensuring efficiency, quality, and reliability throughout the transition.
All nominations and votes come directly from the biopharma community. Winners are chosen by peers based on demonstrated impact, innovation, and contributions to the industry.
